Investigating TRSV Phytoalexin Infusions as a Novel Treatment for Alzheimer’s Disease Using ApoE4 Plasmid Transfections in Neuro2a Cell Complexes
Received Date: April 20, 2020; Published Date: May 12, 2020
Because the accumulation of amyloid plaques plays a central role in the pathogenesis of Alzheimer’s disease (AD) and is responsible for many of its neurodegenerative effects, this project aims to evaluate the effectiveness of TRSV phytoalexin infusions as a novel treatment for the disease by comparing three separate agents and determining its impact on the accumulation of amyloid plaques in mouse Neuro2a cells. The experimental model is as follows: Neuro2a cells were first thawed using incubation and centrifugation techniques. The subculturing protocol was then performed to maximize cellular viability using DPBS and TrypLE dissociation reagents. The cells were transfected with pCMV4-ApoE4 bacterial plasmid using Opti-MEM medium and Lipofectamine LTX while also being treated with phytoalexin agents. Bradford’s assay was performed on the samples using CBB G-250 reagent, and they were run through a spectrophotometer and a Python low-pass filter to generate readings. The experimental data showed that natural grape seed phytoalexin extract was the most effective treating agent, followed by curcumin extract and synthetic RDS phytoalexin. All treating agents lessened the accumulation of the amyloid plaques significantly, supporting the novel infusion protocol as a treatment for AD.
Keywords: Amyloid plaques; ApoE4; Trans-resveratrol; Neuro2a cells; Apolipoprotein E (APOE)
Abbreviations: AD: Alzheimer’s Disease; DPBS- Dulbecco’s Phosphate-Buffered Saline; DMSO- Dimethyl Sulfoxide; CBB- Coomassie Brilliant Blue; TRSV- Trans-Resveratrol; RDS- Resveratrol Dietary Supplement; APOE- Apolipoprotein E; Aβ- Beta Amyloid; APP- Amyloid Precursor Protein; ROSReactive Oxygen Species; AICD- APP Intracellular Domain